^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug Class:Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    A summary of recommendations is presented in Table 6…Summary of recommendations for adult ALL...Targeted therapy with TKIs in Ph+ ALL...A TKI should be combined with chemotherapy in front-line therapy.
    DOI:
    10.1093/annonc/mdw025
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-POSITIVE B-ALL...Other Recommended Regimens...TKIg +...(cyclophosphamide, vincristine, daunorubicin, dexamethasone, cytarabine, methotrexate, pegaspargase, and prednisone)
    Secondary therapy:
    cytarabine + cyclophosphamide + methotrexate + vincristine + daunorubicin + pegaspargase
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-POSITIVE B-ALL...Other Recommended Regimens...TKIg +...(daunorubicin, vincristine, prednisone and cyclophosphamide)
    Secondary therapy:
    cyclophosphamide + vincristine + daunorubicin
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-POSITIVE B-ALL...Other Recommended Regimens...TKIg +...(vincristine + dexamethasone)
    Secondary therapy:
    vincristine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-POSITIVE B-ALL...Other Recommended Regimens...TKIg +...(dexamethasone, vincristine, daunorubicin, methotrexate, etoposide and cytarabine)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR Ph-POSITIVE B-ALL...Other Recommended Regimens...TKIg + hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, prednisone, doxorubicin, and dexamethasone), alternating with high-dose methotrexate and cytarabine.
    Secondary therapy:
    CVAD + cytarabine + methotrexate
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    TCT-ASTCT-CIBMTR 2023
    Title:

    126 - Ph-Positive ALL Patients Who Are Treated with Tyrosine Kinase Inhibitors Have Similar Post-Transplant Survival As Ph-Negative Patients

    Published date:
    12/16/2022
    Excerpt:
    For 2008-2019, Ph+ TKI was associated with improved OS vs Ph+ no TKI (HR=1.32, p=0.008)….Ph+ no TKI patients have inferior survival compared to TKI-treated patients.